Aura Biosciences
Update in progressAURA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing precision therapies for solid tumors. Its platform uses virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. The lead candidate, bel-sar, is in late-stage development for primary choroidal melanoma and other ocular oncology indications, and in early-stage trials for bladder cancer. Founded in 2009, the company is based in Boston, Massachusetts.
Company score
- Sentiment
- 0.51
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.77
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.27
- Governance
- 0.18
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.38
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.44
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!